Jackowski T, Bychowski J. Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2009:161-166.
APA
Jackowski, T., & Bychowski, J. (2009). Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 161-166.
Chicago
Jackowski, Tomasz, and Jerzy Bychowski. 2009. "Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases". Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review: 161-166.
Harvard
Jackowski, T., and Bychowski, J. (2009). Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, pp.161-166.
MLA
Jackowski, Tomasz et al. "Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases." Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 2009, pp. 161-166.
Vancouver
Jackowski T, Bychowski J. Review paperThe usage of the β-adrenolytic drugs by the patients with diabetes and coexisting diseases. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2009:161-166.
Fifty years of experience with the β-adrenolytic drugs provided the solid evidence to recognize their high medical status and importance. But there is still debate about the variuos effects of β-adrenolytic drugs in cardiodiabetology. Diabetes is the metabolic disease that can have a negative impact on the cardiovascular system. Additionally, it can exacerbate already existing disease. The aim of this review is to explore the usage of the β-adrenolytic drugs in the cardiodiabetology.